Literature DB >> 22526604

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

S E Inzucchi1, R M Bergenstal, J B Buse, M Diamant, E Ferrannini, M Nauck, A L Peters, A Tsapas, R Wender, D R Matthews.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22526604     DOI： 10.1007/s00125-012-2534-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  129 in total

1.  Severe iatrogenic hypoglycemia in type 2 diabetes mellitus.

Authors:  Philip E Cryer
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-01

2.  Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.

Authors:  C Lamanna; M Monami; N Marchionni; E Mannucci
Journal:  Diabetes Obes Metab       Date:  2011-03       Impact factor: 6.577

3.  Long-term effects of intensive glucose lowering on cardiovascular outcomes.

Authors:  Hertzel C Gerstein; Michael E Miller; Saul Genuth; Faramarz Ismail-Beigi; John B Buse; David C Goff; Jeffrey L Probstfield; William C Cushman; Henry N Ginsberg; J Thomas Bigger; Richard H Grimm; Robert P Byington; Yves D Rosenberg; William T Friedewald
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

4.  Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know.

Authors:  Robert J Smith; David M Nathan; Silva A Arslanian; Leif Groop; Robert A Rizza; Jerome I Rotter
Journal:  J Clin Endocrinol Metab       Date:  2010-03-01       Impact factor: 5.958

Review 5.  Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors.

Authors:  Jaime A Davidson
Journal:  Mayo Clin Proc       Date:  2010-11-24       Impact factor: 7.616

Review 6.  Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials.

Authors:  Faramarz Ismail-Beigi; Etie Moghissi; Margaret Tiktin; Irl B Hirsch; Silvio E Inzucchi; Saul Genuth
Journal:  Ann Intern Med       Date:  2011-04-19       Impact factor: 25.391

7.  N of 1 trials in diabetes: making individual therapeutic decisions.

Authors:  A Tsapas; D R Matthews
Journal:  Diabetologia       Date:  2008-04-04       Impact factor: 10.122

8.  Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men.

Authors:  K W Chen; E J Boyko; R W Bergstrom; D L Leonetti; L Newell-Morris; P W Wahl; W Y Fujimoto
Journal:  Diabetes Care       Date:  1995-06       Impact factor: 19.112

9.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

Review 10.  Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.

Authors:  Ralph A Defronzo
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112
View more
  459 in total

1.  Diabetes: insulin plus metformin for T2DM--are there benefits?

Authors:  Clifford J Bailey
Journal:  Nat Rev Endocrinol       Date:  2012-06-26       Impact factor: 43.330

2.  Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors.

Authors:  A J Scheen
Journal:  Diabetologia       Date:  2012-07-07       Impact factor: 10.122

3.  Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients.

Authors:  Antoine Pariente; Yohann Mansiaux; Ana Jarné; Francesco Salvo; Cécile Pageot; Julien Bezin; Andy Smith; Bernard Bégaud
Journal:  Eur J Clin Pharmacol       Date:  2017-09-02       Impact factor: 2.953

Review 4.  Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

5.  Risk of Type 2 Diabetes Among Lesbian, Bisexual, and Heterosexual Women: Findings From the Nurses' Health Study II.

Authors:  Heather L Corliss; Nicole A VanKim; Hee-Jin Jun; S Bryn Austin; Biling Hong; Molin Wang; Frank B Hu
Journal:  Diabetes Care       Date:  2018-05-02       Impact factor: 19.112

6.  Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy.

Authors:  C D Andersen; L Bennet; L Nyström; U Lindblad; E Lindholm; L Groop; O Rolandsson
Journal:  Diabetologia       Date:  2012-10-25       Impact factor: 10.122

Review 7.  Anti-diabetic medications: How to make a choice?

Authors:  Amir Babiker; Mohammed Al Dubayee
Journal:  Sudan J Paediatr       Date:  2017

Review 8.  Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective.

Authors:  Mala Dharmalingam
Journal:  Ther Adv Endocrinol Metab       Date:  2014-12       Impact factor: 3.565

9.  Age-related differences in glycaemic control in diabetes.

Authors:  Elizabeth Selvin; Christina M Parrinello
Journal:  Diabetologia       Date:  2013-10-05       Impact factor: 10.122

Review 10.  Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.